Efficacy and Safety of Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial

Goldberg, Anne C.; Sapre, Aditi; Ji Liu; Capece, Rachel; Mitchel, Yale B.
May 2004
Mayo Clinic Proceedings;May2004, Vol. 79 Issue 5, p620
Academic Journal
• Objective: To compare the efficacy and safety of 10 mg of ezetimibe coadministered with simvastatin with the safety and efficacy of simvastatin monotherapy for patients with hypercholesterolemia. • Patients and Methods: This multicenter double-blind, placebo-controlled, factorial study enrolled 887 patients with hypercholesterolemia (low-density lipoprotein cholesterol [LDL-C], 145-250 mg/dL; triglycerides, ≤350 mg/ dL). Patients were randomized to 1 of 10 treatments— placebo, ezetimibe at 10 mg/d, simvastatin at 10, 20, 40, or 80 mg/d, or simvastatin at 10, 20, 40, or 80 mg/d plus ezetimibe at 10 mg/d for 12 weeks. The study began March 13, 2001, and ended January 8, 2002. The primary efficacy end point was the mean percent change in LDL-C levels from baseline to study end point (last available postbaseline LDL-C measurement) for the pooled ezetimibe/simvastatin group vs the pooled simvastatin monotherapy group. • Results: Coadministration of ezetimibe/simvastatin was significantly (P<.001) more effective than simvastatin alone in reducing LDL-C levels for the pooled ezetimibe/ simvastatin vs pooled simvastatin analysis and at each specific dose comparison. The decrease in LDL-C levels with coadministration of ezetimibe and the lowest dose of simvastatin, 10 mg, was similar to the decrease with the maximum dose of simvastatin, 80 mg. A significantly (P<.001) greater proportion of patients in the ezetimibe/ simvastatin group achieved target LDL-C levels compared with those in the monotherapy group. Treatment with ezetimibe/simvastatin also led to greater reductions in total cholesterol, triglyceride, non-high-deusity lipoprotein cholesterol, and apolipoprotein B levels compared with simvastatin alone; both treatments increased high-density lipoprotein cholesterol levels similarly. The safety and tolerability profiles for the ezetimibe/simvastatin and monotherapy groups were similar. • Conclusion: Through dual inhibition of cholesterol absorption and synthesis, coadministration of ezetimibe/ simvastatin offers a highly efficacious and well-tolerated lipid-lowering strategy for treating patients with primary hypercholesterolemia.


Related Articles

  • Emerging Options for Treating Patients with Severe Hypercholesterolemia. Stroes, Erik S. G. // Cardiology Today;Feb2012 Supplement, p13 

    The article suggests the emerging therapeutic approaches for patients with severe hypercholesterolemia, including statin-based lipid lowering and low-density lipoprotein LD) lowering strategies.

  • RUTHERFORD: PCSK9 inhibition improved LDL in patients with familial hypercholesterolemia. Costa, Samantha; Ellis, Brian; Foster, Melissa; Kalvaitis, Katie; Volansky, Rob // Endocrine Today;Dec2012, Vol. 10 Issue 12, p22 

    The article focuses on the results from the phase 2 RUTHERFORD trial which showed AMG 145 being responsible for low-density lipoprotein (LDL) reductions of up to 56% in combination with statin therapy with or without ezetimibe for patients with heterozygous familial hypercholesterolemia.

  • Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Bell, Damon A.; Hooper, Amanda J.; Watts, Gerald F.; Burnett, John R. // Vascular Health & Risk Management;2012 Part 2, Vol. 8, p651 

    Familial hypercholesterolemia (FH) is an autosomal dominant condition with a population prevalence of one in 300-500 (heterozygous) that is characterized by high levels of low-density lipoprotein (LDL) cholesterol, tendon xanthomata, and premature atherosclerosis and coronary heart disease...

  • Red yeast rice and LDL. Elliott, William T. // Clinical Cardiology Alert;Aug2009 Pharmacology Watch, p2 

    The article discusses research on the therapeutic use of red yeast rice for hypercholesterolemia. It references a study published in the 2009 issue of "Annals of Internal Medicine." The study included 31 patients with a history of statin-associated myalgias, who were randomized to either receive...

  • Red yeast rice and LDL. Elliott, William T. // Primary Care Reports;Aug2009 Supplement, p2 

    The article discusses research on the therapeutic use of red yeast rice for hypercholesterolemia. It references a study published in the 2009 issue of "Annals of Internal Medicine." The study included 31 patients with a history of statin-associated myalgias, who were randomized to either receive...

  • Use of ezetimibe in lowering cholesterol. Ferro, Albert // Pulse;2/16/2004, Vol. 64 Issue 7, p84 

    Answers a question on the use of ezetimibe in lowering cholesterol. Role in lipid regulation; Indication for monotherapy or with statins in patients with hypercholesterolemia; Reduction of intestinal cholesterol absorption.

  • Rosuvastatin reigns supreme for hypercholesterolaemia.  // PharmacoEconomics & Outcomes News;11/3/2007, Issue 540, p5 

    The article focuses on a study on the cost effectiveness of rosuvastatin for the treatment of hypercholesterolaemia in Canada. It states that the cost effectiveness of rosuvastatin against atorvastatin, pravastatin and simvastatin among patients with hypercholesterolaemia was evaluated. It cites...

  • Effect of Nicorandil: A Potassium Channel Opener against Experimentally-induced Hyperlipidemia. Rathod, D. M.; Dodiya, H. G.; Goswami, S. S. // International Journal of Pharmacology;2011, Vol. 7 Issue 6, p690 

    Hypercholesterolemia often occurs in conjunction with other metabolic risk factors including glucose intolerance, obesity, diabetes and metabolic syndromes. Nicorandil is a potassium channel opener and Nitric Oxide (NO) donor. The aim of study was to evaluate pharmacological effect of nicorandil...

  • Efficacy and Safety of Chitosan HEP-40 in the Management of Hypercholesterolemia: A Randomized, Multicenter, Placebo-controlled Trial. Jaffer, Shahin; Sampalis, John S. // Alternative Medicine Review;Sep2007, Vol. 12 Issue 3, p265 

    BACKGROUND: Hypercholesterolemia is an important risk factor for cardiovascular disease (CVD). OBJECTIVE: To compare the efficacy of a 12-week treatment regimen with HEP-40â„¢ low-molecular weight chitosan given at daily doses of 1,200 mg, 1,600 mg, and 2,400 mg in reducing serum low-density...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics